Literature DB >> 2508448

Inhibition of platelet-derived mitogen release by nitric oxide (EDRF).

M L Barrett1, A L Willis, J R Vane.   

Abstract

Platelets exposed to thrombogenic surfaces adhere, aggregate and release mitogenic substances from their alpha-granules. Endothelium-derived relaxing factor (EDRF) which has been identified as nitric oxide (NO) has been reported to inhibit platelet aggregation. We now report that NO inhibits mitogen release from stimulated human platelets. Mitogenic activity was assayed on mouse fibroblast 3T3 cells using incorporation of 3H-thymidine. Serum from collagen-aggregated platelets significantly increased 3H-thymidine incorporation by 3T3 cells above that of serum from control platelets. Both this increase and platelet aggregation were blocked by NO and prostacyclin in a dose related manner. The inhibitory activity of NO decayed with time when incubated in platelet-free plasma at 37 degrees C, but was still detectable after 2 minutes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2508448     DOI: 10.1007/bf01972860

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  9 in total

Review 1.  The biology of platelet-derived growth factor.

Authors:  R Ross; E W Raines; D F Bowen-Pope
Journal:  Cell       Date:  1986-07-18       Impact factor: 41.582

2.  Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries.

Authors:  U Förstermann; A Mügge; U Alheid; A Haverich; J C Frölich
Journal:  Circ Res       Date:  1988-02       Impact factor: 17.367

3.  Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets.

Authors:  M W Radomski; R M Palmer; S Moncada
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

Review 4.  Suppression of principal atherosclerotic mechanisms by prostacyclins and other eicosanoids.

Authors:  A L Willis; D L Smith; C Vigo
Journal:  Prog Lipid Res       Date:  1986       Impact factor: 16.195

5.  Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium.

Authors:  M W Radomski; R M Palmer; S Moncada
Journal:  Lancet       Date:  1987-11-07       Impact factor: 79.321

Review 6.  A reappraisal of nitrate therapy.

Authors:  J Abrams
Journal:  JAMA       Date:  1988-01-15       Impact factor: 56.272

7.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.

Authors:  R M Palmer; A G Ferrige; S Moncada
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

8.  Vasoconstriction: a new activity for platelet-derived growth factor.

Authors:  B C Berk; R W Alexander; T A Brock; M A Gimbrone; R C Webb
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

Review 9.  Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials.

Authors:  S Yusuf; R Collins; S MacMahon; R Peto
Journal:  Lancet       Date:  1988-05-14       Impact factor: 79.321

  9 in total
  4 in total

Review 1.  Endothelial dysfunction, inflammation and diabetes.

Authors:  Paresh Dandona; Ahmad Aljada; Ajay Chaudhuri; Priya Mohanty
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 2.  St Cyres lecture. Endothelium in control.

Authors:  A H Henderson
Journal:  Br Heart J       Date:  1991-03

Review 3.  NO: COPD and beyond.

Authors:  A T Jones; T W Evans
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

4.  Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension.

Authors:  S A Kharitonov; J B Cailes; C M Black; R M du Bois; P J Barnes
Journal:  Thorax       Date:  1997-12       Impact factor: 9.139

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.